{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T16:46:51Z","timestamp":1774975611526,"version":"3.50.1"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Institute of Oncology"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Renal cell carcinoma is a challenging malignancy that often necessitates advanced systemic therapies. Immunotherapy with checkpoint inhibitors has emerged as a cornerstone for managing advanced renal cell carcinoma. This case highlights the clinical course, treatment response, and management of complications in a patient with advanced renal cell carcinoma treated with immunotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 51-year-old white male patient presented with dizziness, leading to a diagnosis of advanced renal cell carcinoma involving a large left renal mass, pulmonary metastases, and retroperitoneal lymphadenopathy. After radical nephrectomy in 2016, histopathology confirmed T3a clear cell carcinoma with vascular invasion. Initial systemic treatment included targeted therapy with sunitinib, followed by axitinib owing to disease progression. Nivolumab, a programmed death-1 inhibitor, became available in Hungary in 2018 and was initiated as third-line therapy in mid-2018. The patient has remained disease-free without any therapy for the past 27\u00a0months, with follow-up imaging through September 2025 confirming sustained complete remission first documented in October 2020, amounting to nearly 5 years of continuous complete remission. The patient experienced manageable immune-related adverse events, including nephritis and colitis, which were treated with corticosteroid therapy. Routine imaging and clinical assessments confirmed no evidence of recurrence as of September 2025. This case underscores the efficacy and durability of immune checkpoint inhibitors in advanced renal cell carcinoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case exemplifies the long-term benefit of immunotherapy in advanced renal cell carcinoma, emphasizing the importance of vigilant monitoring for immune-related adverse events, sustained follow-up, and the potential for extended therapy-free remission.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13256-026-05886-3","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T18:55:46Z","timestamp":1772045746000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Sustained complete remission with third-line nivolumab in advanced renal cell carcinoma: a case report"],"prefix":"10.1186","volume":"20","author":[{"given":"Zs\u00f3fia","family":"K\u00fcronya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enik\u0151","family":"L\u00e9n\u00e1rt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edina","family":"So\u00f3s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lajos","family":"G\u00e9czi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krisztina","family":"Bir\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"issue":"3","key":"5886_CR1","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41585-020-0282-3","volume":"17","author":"W Xu","year":"2020","unstructured":"Xu W, Atkins MB, McDermott DF. Checkpoint inhibitor immunotherapy in kidney cancer. Nat Rev Urol. 2020;17(3):137\u201350.","journal-title":"Nat Rev Urol"},{"issue":"19","key":"5886_CR2","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et\u00a0al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803\u201313.","journal-title":"N Engl J Med"},{"issue":"7_suppl","key":"5886_CR3","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1200\/JCO.2019.37.7_suppl.645","volume":"37","author":"R Elias","year":"2019","unstructured":"Elias R, Yan F, Singla N, Levonyack N, Formella J, Christie A, et\u00a0al. Immune related adverse events are associated with improved outcomes in ICI treated renal cell carcinoma patients. J Clin Oncol. 2019;37(7_suppl):645\u2013645.","journal-title":"J Clin Oncol"},{"issue":"12","key":"5886_CR4","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1007\/s10147-023-02406-x","volume":"28","author":"S Washino","year":"2023","unstructured":"Washino S, Shirotake S, Takeshita H, Inoue M, Miura Y, Hyodo Y, et\u00a0al. Association between immune-related adverse events and survival in patients with renal cell carcinoma treated with nivolumab plus ipilimumab: immortal time bias-corrected analysis. Int J Clin Oncol. 2023;28(12):1651\u20138.","journal-title":"Int J Clin Oncol"},{"issue":"36","key":"5886_CR5","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, et\u00a0al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021;39(36):4073\u2013126.","journal-title":"J Clin Oncol"},{"issue":"15","key":"5886_CR6","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1158\/1078-0432.CCR-23-3719","volume":"30","author":"E Chang","year":"2024","unstructured":"Chang E, Zhou J, Song C, Gittleman H, Fernandes L, Weinstock C, et\u00a0al. A pooled analysis of treatment-free survival in advanced renal cell carcinoma. Clin Cancer Res. 2024;30(15):3282\u20136.","journal-title":"Clin Cancer Res"},{"issue":"24","key":"5886_CR7","doi-asserted-by":"publisher","first-page":"6687","DOI":"10.1158\/1078-0432.CCR-21-2283","volume":"27","author":"MM Regan","year":"2021","unstructured":"Regan MM, Jegede OA, Mantia CM, Powles T, Werner L, Motzer RJ, et\u00a0al. Treatment-free survival after immune checkpoint inhibitor therapy versus targeted therapy for advanced renal cell carcinoma: 42-month results of the checkmate 214 trial. Clin Cancer Res. 2021;27(24):6687\u201395.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"5886_CR8","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/iju5.12139","volume":"3","author":"R Kurahashi","year":"2020","unstructured":"Kurahashi R, Motoshima T, Fukushima Y, Murakami Y, Yatsuda J, Yamaguchi T, et\u00a0al. Remarkable antitumor effect of nivolumab in a patient with metastatic renal cell carcinoma previously treated with a peptide-based vaccine. IJU Case Reports. 2020;3(2):44\u20138.","journal-title":"IJU Case Reports"},{"key":"5886_CR9","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.5531","author":"S Vuyyala","year":"2019","unstructured":"Vuyyala S, Gandhi S, Kuechle JB, George S. Complete remission of bone metastases in renal cell carcinoma with nivolumab. Cureus. 2019. https:\/\/doi.org\/10.7759\/cureus.5531.","journal-title":"Cureus"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-026-05886-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-026-05886-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-026-05886-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T15:24:43Z","timestamp":1774970683000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13256-026-05886-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":9,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5886"],"URL":"https:\/\/doi.org\/10.1186\/s13256-026-05886-3","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]},"assertion":[{"value":"30 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics committee approval was obtained from the regional ethical committee (reference no. OOI\/\u00c1lt02002-1\/2025).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"155"}}